Management of kidney cancer patients: 2018 guidelines of the Italian Medical Oncology Association (AIOM)

In the past two decades, the treatment landscape for patients with metastatic renal cell carcinoma has significantly changed thanks to the approval of several targeted molecular therapies (VEGF and mTOR inhibitors) and recently immune-checkpoint inhibitors. The Italian Association of Medical Oncolog...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Tumori 2019-07, Vol.105 (4_suppl), p.3-12
Hauptverfasser:	Giuseppa Vitale, Maria, Bracarda, Sergio, Cosmai, Laura, Crocetti, Emanuele, Di Lorenzo, Giuseppe, Lapini, Alberto, Mandressi, Alberto, Martorana, Giuseppe, Masini, Cristina, Montironi, Rodolfo, Ortega, Cinzia, Passalacqua, Rodolfo, Porta, Camillo, Procopio, Giuseppe, Sepe, Pierangela, Romano, Luigia, Luigi Pappagallo, Giovanni, Conti, Giario, Guida, Michele, Martignoni, Guido, Nolè, Franco, Pignata, Sandro, Gori, Stefania, Cartenì, Giacomo
Format:	Artikel
Sprache:	eng
Schlagworte:	Carcinoma - drug therapy Carcinoma, Renal Cell - drug therapy Humans Italy Kidney Neoplasms - drug therapy Medical Oncology - standards
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In the past two decades, the treatment landscape for patients with metastatic renal cell carcinoma has significantly changed thanks to the approval of several targeted molecular therapies (VEGF and mTOR inhibitors) and recently immune-checkpoint inhibitors. The Italian Association of Medical Oncology (AIOM) Renal Cell Cancer (RCC) Guidelines Panel has developed clinical guidelines to provide evidence-based information and recommendations to oncologists, urologists and all professionals involved in the management of patients with renal cell cancer.
ISSN:	0300-8916 2038-2529
DOI:	10.1177/0300891619853392